loader2
Partner With Us NRI

Laurus Labs Ltd share Price Today

Company details

389.55
396.25
278.85
444.70
6M Return -0.43%
1Y Return 31.75%
Mkt Cap.(Cr) 21,146.33
Volume 1,534,903
Div Yield 0.51%
OI
-
OI Chg %
-
Volume 1,534,903

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Slowdown in custom synthesis weighs on numbers..
About The Stock

    Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs.

    • It has 11 manufacturing units (six FDA approved sites) with 73 DMFs, 31 ANDAs filed (15 Para IV, 10 first to file) and 184 patents granted
    • Laurus acquired Richore Life Sciences to diversify in area of recombinant animal origin free products, enzymes as well as building biologics CDMO
Q4FY22

    Significant beat propelled by synthesis and formulations.

    • Sales were up 1% YoY to ₹ 1425 crore, which were optically muted due to ARVs destocking impact during the year and a high base of Q4FY21
    • EBITDA was at ₹ 397 crore, down 16% YoY with margins at 27.8%
    • Adjusted PAT was at ₹ 230.5 crore (down 22% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Laurus Labs announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Revenue was Rs 1,224 crore, a 22% YoY decrease. Excluding Purchase Orders, there was an 18% growth.
    • EBITDA was Rs 188 crore, down 58% YoY.
    • EBITDA margins stood at 15.4%.
    • Profit After Tax (PAT) amounted to Rs 37 crore, down 84% YoY.
    • PAT margins were at 3.0%.
    • Earnings Per Share (EPS) for the period, on a diluted basis, were Rs 0.6 per share (not annualized).
  • H1FY24:
    • Revenue was Rs 2,406 crore, showing a 23% YoY decrease. Excluding Purchase Orders, there was a 14% growth.
    • EBITDA amounted to Rs 356 crore, indicating a substantial 61% YoY decline.
    • EBITDA margins were at 14.8%.
    • Profit After Tax (PAT) was Rs 62 crore, down by 87% YoY.
    • PAT margins stood at 2.6%.
    • Earnings Per Share (EPS) for the period, on a diluted basis, were Rs 1.1 per share (not annualized).
    • An interim dividend of Rs 0.40 per share was declared.

Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated, “ImmunoAct associate company of Laurus became the first strategic collaboration to win marketing approval for India’s first CAR-T therapy, NexCAR19. We are proud of this important innovative breakthrough in treating blood cancer. We feel a combination of their pipeline, technology and Laurus' support in building manufacturing capabilities will accelerate our pursuit of next-generation innovation in cell therapies and new drug discovery. Q2 operating results started to improve and the health of our businesses is intact. Momentum in generic business has picked up during the quarter and CDMO-Synthesis is stable with a healthy scale-up in the project pipeline along with the expansion of our strategic partnerships. Our investments in transformative technology platforms are making good progress and future CDMO growth prospects are very encouraging. The recovery we saw in the quarter gives us confidence that we will have a better H2 resulting from both a healthy order book and strong commercial execution. Our priorities remain consistent on ensuring greater business resilience by accelerating our scientific advantage to deliver the best external and internal opportunities as well as long-term value creation.”

 

 

Result PDF

View Other Company Results

Laurus Labs Ltd shares SWOT Analysis

Strengths (4)

  • Company with Low Debt
  • Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
  • Book Value per share Improving for last 2 years

Weakness (9)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (0)

Data not found

Threats (3)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 395.9
R2 399.4
R3 402.6
Pivot

392.72

S1 389.2
S2 386.0
S3 382.5
EMA SMA
397.8
399.4
396.2
391.7
402.4
398.4
396.5
387.1
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ARUN VIJAY NATHANI Block Purchase 2023-03-14 305 635894 NSE
CYBAGE SOFTWARE PRIVATE LIMITED Block Sell 2023-03-14 305 635894 NSE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-11-14 455.4 529337 NSE
Name Category Shares
CHUNDURU VENKATA LAKSHMANA RAO PROMOTER 2.5%
M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava) PROMOTER 23.03%
M/s. Leven Holdings (Represented by its Managing Partner, Mr. Venkata Ravi Kumar Vantaram) PROMOTER 1.24%

OUR RESEARCH VIEW

Investment recommendation
Slowdown in custom synthesis weighs on numbers..
Call Date
28 Apr 2023
Entry Price 292.00
Target Price 300.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Laurus Labs Ltd Stocks COMPARISON

Financials( in Cr) Laurus Labs Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 392.35 1,620.55 1,496.95 6,157.90 1,007.35
% Change 0.04 1.02 2.30 1.88 0.77
Mcap Cr 21,146.33 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 6,040.55 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 796.64 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 112.25 41.45 30.52 19.64 30.51
1 Year Return 31.75 64.78 68.33 37.28 109.04
ROCE 21.78 16.79 14.76 25.99 16.25
ROE 21.56 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 4,037.53 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,068.81 33,709.58
LAST 3M 68,518.10 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,941.35 208,211.24

Laurus Labs Ltd Information

Stock PE (TTM)
112.25
Promoter Holding
27.19%
Book Value
74.7707
ROCE
21.78%
ROE
21.56%
Description
  • Laurus Labs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 37508.48 crores, it is incorporated in the year 2005. It features consolidated sales of Rs. 1220.60 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 540222 and additionally listed in the National Stock Exchange (NSE) with the code LAURUSLABS.

    Laurus Labs is one of the top pharmaceuticals companies in the country, holding a leadership position in research & development and manufacturing of generic APIs. The company is also working with several top pharmaceuticals companies worldwide for research & development with a primary focus on anti-retroviral, Hepatitis C, and Oncology drugs. The company also owns around 155 patents. The headquarters of Laurus labs are situated in the city of Hyderabad, while its manufacturing plants are located in Visakhapatnam, Hyderabad, and Bengaluru. Laurus Labs has also received several approvals from major regulatory medical bodies worldwide, such as WHO, USFDA, KFDA, MHRA, etc. In March’20, Laurus Labs received approval from USFDA for hydroxychloroquine tablets, which were initially used to treat the COVID-19 patients. The promoters within the company currently hold 53.56% of the stake in the company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 6.65% and 3.44% of the stake. The balance of 36.35% is by others (retail investors).

    In June 2021, quarterly net sales were Rs. 1,220.6 crores, which has increased by approximately 25.78% from Rs. 970.4 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 222.08 crores, which has grown by 39.87% from a net profit of Rs. 158.78 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,032.11 crores, which is also increased by 25.79% as compared to an operating profit of Rs. 820.49 crores for the quarter ending in June 2020. From Rs. 2.97 in June 2020, the EPS of Laurus Labs has grown to just Rs. 4.14 per share in June 2021. LAURUSLABS’s stock closed at Rs. 689.35 on 16th August’2021 (NSE) and has returned 86.97% in the last six months and 234.49% within the last year.

Registered Address

Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021

Tel : 91-891-3061222
Email : secretarial:lauruslabs.com; info:lauruslabs.com
Website : http://www.lauruslabs.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 540222
NSE Code : LAURUSLABS
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE947Q01028

FAQ’s on Laurus Labs Ltd Shares

You can buy Laurus Labs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Laurus Labs Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 03:59 PM the closing price of Laurus Labs Ltd was ₹ 392.35.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 03:59 PM, the market cap of Laurus Labs Ltd stood at ₹ 21,146.33.

The latest PE ratio of Laurus Labs Ltd as of Mar 28, 2024 03:59 PM is 112.25

The latest PB ratio of Laurus Labs Ltd as of Mar 28, 2024 03:59 PM is 0.19

The 52-week high of Laurus Labs Ltd share price is ₹ 444.70 while the 52-week low is ₹ 278.85

According to analyst recommendations, Laurus Labs Ltd Share has a “Buy” rating for the long term.

Download Our

Download App
market app